Corbus Pharma’s IND Application Gets FDA Clearance For Investigational Drug CRB-601
Corbus Pharmaceuticals Holdings, Inc. Tuesday announced FDA clearance for its investigational new drug or IND application of CRB-601, a TGFß blocking monoclonal antibody targeting the integrin avß8. Read more >>